Pyrovalerone was originally prescribed for chronic fatigue and obesity in the 1960s at daily doses of 60 mg (20 mg three times daily), but patients frequently developed tolerance and compulsive redosing, leading to discontinuation of its clinical use. Modern reports describe it as a stimulant with a profile between methylphenidate and MDPV, with strong drive to redose every 2-3 hours. Its pharmacology shows high affinity inhibition of dopamine and norepinephrine transporters, with negligible serotonin activity. The short half-life contributes to a sharp comedown marked by irritability, low mood, and insomnia. Accurate dosing is critical as pyrovalerone is active at low milligram amounts, making volumetric measurement safer than weighing single doses.
Pyrovaleroni molecular structure diagram from the DrugsPRO substance library.
Also known as: Pyrovaleron, O-2371, Centroton, Thymergix, 4-methyl-β-keto-prolintane, Beta-keto-prolintane, pirovalerone
Classification
Chemical: Cathinone
Psychoactive: Stimulant
Tag: Pyrrolidine
Tag: Pyrrolidinophenone
Tag: Research-Chemical
Effects
Stimulation
Teeth Grinding
Increased Heart Rate
Loss Of Appetite
Dry Mouth
Tremor
Motivation Enhancement
Euphoria
Increased Focus
Anxiety
Compulsive Redosing
Irritability
Appetite Suppression
Light Sensitivity
Tactile Enhancement
Increased Libido
Disinhibition
Dehydration
Routes of Administration
Oral
Dosage
Threshold: 5–10 mg
Light: 10-25 mg
Common: 25-60 mg
Strong: 60-100 mg
Heavy: 100+ mg
Duration
Onset: 0.17-0.5 h
Comeup: 0.5-1 h
Peak: 0.5-2 h
Offset: 1-3 h
After Effects: 2-24 h
Total Duration: 3-6 h
Insufflated
Dosage
Threshold: 3–5 mg
Light: 5-15 mg
Common: 15-40 mg
Strong: 40-80 mg
Heavy: 80+ mg
Duration
Onset: 0.08-0.17 h
Comeup: 0.25-0.5 h
Peak: 0.25-1 h
Offset: 1-2.5 h
After Effects: 2-24 h
Total Duration: 2.5-5 h
Rectal
Dosage
Threshold: 3–5 mg
Light: 5-15 mg
Common: 15-35 mg
Strong: 35-70 mg
Heavy: 70+ mg
Duration
Onset: 0.17-0.33 h
Comeup: 0.33-0.67 h
Peak: 0.5 h
Offset: 1-3 h
After Effects: 2-24 h
Intravenous
Dosage
Threshold: 0.5–1 mg
Light: 1-5 mg
Common: 5-15 mg
Strong: 15-30 mg
Heavy: 30+ mg
Duration
Onset: 0.02-0.05 h
Comeup: 0.03-0.08 h
Peak: 0.05-0.5 h
Offset: 0.5-2 h
After Effects: 2-24 h
Total Duration: 2-4 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
Pyrovalerone - DrugsPRO aineopas
Pyrovalerone: Pyrovalerone was originally prescribed for chronic fatigue and obesity in the 1960s at daily doses of 60 mg (20 mg three times daily), but patients frequently developed tolerance and compulsive redosing, leading to discontinuation of its clinical use. Modern reports describe it as a st
